Poxel Mutual Funds | StatInvestor

Health Care & Life Sciences » Biotechnology | Poxel

Poxel S.A. | Mutual Funds

Mutual Funds that own Poxel S.A.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Federated Kaufmann Fund

880,000

3.58%

0.1%

06/29/2018

Adamant Global Biotech

121,120

0.49%

-5,500

0.77%

12/29/2017

Etoile Santé Europe

88,020

0.36%

0.35%

01/31/2018

Amundi Actions Restructurations

72,718

0.3%

0.1%

01/31/2018

LBPAM Actions Santé

61,029

0.25%

0.32%

06/29/2018

Amundi Europe Micro Caps

55,005

0.22%

0.25%

01/31/2018

Tocqueville PME

33,534

0.14%

0.36%

07/31/2018

Gestys Santé Biotech

25,000

0.1%

5,000

5.35%

03/23/2018

Actys 1

24,713

0.1%

0.52%

06/29/2018

Federated Kaufmann II Fund

22,220

0.09%

0.1%

06/29/2018

About Poxel

View Profile

Address	259/261, avenue Jean Jaurès Lyon Rhone-Alpes 69007 France
Employees	-
Website	http://www.poxel.com
Updated	07/08/2019
Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.